Wegovy Cost in Indiana (2026): Prices, Insurance, and Savings Options

What Wegovy Costs at Indiana Pharmacies in 2026

The manufacturer list price set by Novo Nordisk for Wegovy is $1,349 per month, and Indiana retail pharmacies charge that same figure for cash-pay customers. This price applies to the maintenance dose of semaglutide 2.4 mg administered once weekly by subcutaneous injection. The cost remains consistent across chain pharmacies in Indianapolis, Fort Wayne, Evansville, and South Bend.

That $1,349 figure covers four pre-filled pens (one per week). Patients in the 16-week dose-escalation phase pay the same monthly rate despite receiving lower milligram doses, because Novo Nordisk packages each escalation tier as a single monthly carton. Some patients have reported slight price variation ($10 to $30) between independent Indiana pharmacies and national chains like CVS, Walgreens, and Kroger, but the differences are marginal.

Without insurance or a discount program, the annual cost reaches approximately $16,188. That number puts Wegovy out of reach for many Hoosiers, which is why understanding insurance coverage, savings programs, and compounded alternatives matters. Indiana's adult obesity rate sits at 36.8% according to the CDC's Behavioral Risk Factor Surveillance System, making access to GLP-1 receptor agonists a pressing public health question in the state.

Novo Nordisk did not reduce its list price in 2025 or the first half of 2026. Price negotiations happen at the pharmacy benefit manager (PBM) level, so the effective price varies by plan.

Indiana Medicaid Coverage for Wegovy

Indiana Medicaid does not cover Wegovy when prescribed for chronic weight management. Coverage is limited to semaglutide for type 2 diabetes under the Ozempic brand name, which uses different dosing (0.5 mg, 1 mg, or 2 mg rather than 2.4 mg). This restriction applies to both traditional Medicaid and Indiana's Healthy Indiana Plan (HIP).

The exclusion follows a pattern across many state Medicaid programs. The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity recommended that insurers cover FDA-approved anti-obesity medications, noting that "pharmacotherapy for obesity should be available to all patients who meet treatment criteria." Indiana has not adopted that recommendation for its Medicaid formulary.

Patients on Indiana Medicaid who also carry a type 2 diabetes diagnosis may access semaglutide through the Ozempic formulary pathway. The prescribing indication matters: a provider must document glycemic control as the primary treatment goal. Off-label Wegovy prescribing through Medicaid is not reimbursed.

There is no pending Indiana legislation as of May 2026 that would mandate Medicaid coverage for anti-obesity medications. Advocacy groups including the Obesity Action Coalition continue to push for policy change at the state level, but Hoosier Medicaid enrollees currently have no covered pathway to Wegovy for weight loss alone.

Which Indiana Insurance Plans Cover Wegovy

Commercial insurance coverage for Wegovy in Indiana varies by employer, plan tier, and PBM. Large self-insured employers are more likely to include GLP-1 receptor agonists on their formularies than small-group or individual marketplace plans.

Plans that do cover Wegovy typically require prior authorization. Common criteria include a documented BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia), a record of failed lifestyle intervention (diet and exercise for 3 to 6 months), and prescriber attestation. Some plans also require step therapy, meaning the patient must try an older agent like phentermine or orlistat before gaining Wegovy approval.

Among Indiana's largest insurers, Anthem Blue Cross and Blue Shield covers Wegovy on select employer-sponsored plans with prior authorization. UnitedHealthcare includes Wegovy on certain commercial formularies but excludes it on others. CareSource, which administers HIP plans, does not cover Wegovy for weight management under its Medicaid line.

Copays for commercially insured patients who do gain approval range from $25 to $250 per month depending on formulary tier placement. Specialty tier placement (Tier 4 or Tier 5) results in higher out-of-pocket costs. Patients should call the number on their insurance card and ask specifically whether "semaglutide 2.4 mg, brand Wegovy" is covered, since the answer may differ from coverage for semaglutide at diabetes doses.

A 2024 analysis published in JAMA Network Open found that only 25% of large commercial plans covered at least one GLP-1 receptor agonist for obesity by mid-2024, though that percentage has been climbing.

How the Novo Nordisk Savings Card Works in Indiana

Novo Nordisk offers a manufacturer savings card for Wegovy that can reduce the monthly out-of-pocket cost to as little as $0 for eligible patients with commercial insurance. The card is not available to patients on Medicare, Medicaid, TRICARE, or other government-funded programs.

Eligibility requirements are straightforward. The patient must have commercial insurance that covers Wegovy (even with a high copay), a valid prescription, and U.S. residency. The savings card covers up to $500 per 28-day supply, meaning a patient with a $200 specialty copay would pay nothing, while a patient with a $600 copay would pay $100.

Activation happens online through the Novo Nordisk patient portal or by phone. The pharmacy processes the savings card as a secondary payer after running the primary insurance claim. Indiana pharmacies, including all major chains, accept the card.

One limitation: the savings card does not help uninsured patients or patients whose plans explicitly exclude Wegovy. For those individuals, the card has no claim to apply against. Novo Nordisk also operates a patient assistance program (PAP) for uninsured patients with household income below 400% of the federal poverty level. That program provides Wegovy at no cost but requires a separate application and income verification.

Compounded Semaglutide 2.4 mg in Indiana: Legality and Cost

Compounded semaglutide 2.4 mg is available in Indiana through licensed 503A compounding pharmacies at roughly $199 per month. That price represents an 85% reduction compared to brand Wegovy.

The legal framework is clear. Under the Federal Food, Drug, and Cosmetic Act Section 503A, a licensed compounding pharmacy may prepare a compounded version of semaglutide when a prescriber writes a patient-specific prescription. The pharmacy must compound from bulk pharmaceutical-grade semaglutide base, follow current good manufacturing practices, and hold a valid Indiana Board of Pharmacy license. Indiana does not impose additional state-level restrictions beyond federal 503A requirements.

The FDA's position on compounded semaglutide has evolved. In October 2023, semaglutide appeared on the FDA drug shortage list, which expanded 503B outsourcing facilities' ability to compound it. As of 2026, the shortage status has fluctuated, and patients should confirm current FDA shortage-list status before assuming 503B availability.

Quality varies between compounders. Patients should verify that the pharmacy is licensed by the Indiana Board of Pharmacy, accredited by the Pharmacy Compounding Accreditation Board (PCAB), and willing to provide a certificate of analysis (COA) for potency and sterility testing. Not all compounded semaglutide products undergo third-party testing.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has noted: "Patients considering compounded GLP-1 agonists should confirm the pharmacy's accreditation status and request documentation of potency testing for each batch."

Compounded semaglutide is typically dispensed as a multi-dose vial requiring the patient to draw and inject the correct volume, unlike the pre-filled Wegovy pen. Dose accuracy depends on proper syringe technique. Providers prescribing compounded semaglutide should ensure patients receive injection training.

Getting Wegovy via Telehealth in Indiana

Indiana permits telehealth prescribing of Wegovy. No in-person visit is required for an initial prescription, provided the prescriber conducts an appropriate clinical evaluation via synchronous audio-video consultation. Indiana follows the Ryan Haight Act for controlled substances, but semaglutide is not a controlled substance, so those restrictions do not apply.

Several national telehealth platforms operate in Indiana and prescribe Wegovy or compounded semaglutide, including HealthRX, Calibrate, Found, and Ro. Pricing models differ. Some charge a monthly membership fee ($50 to $199 per month) plus medication cost, while others bundle the consultation into the medication price.

For Indiana patients, telehealth offers two practical advantages. First, wait times are shorter than the 3 to 8 week average for a new-patient appointment with an Indiana endocrinologist or obesity medicine specialist, particularly in rural counties. Second, telehealth providers that partner with compounding pharmacies can ship compounded semaglutide directly to the patient's door, avoiding the need to locate an in-state 503A pharmacy willing to fill the prescription.

The prescribing clinician must hold an active Indiana medical license or practice under a valid interstate compact. Indiana is a member of the Interstate Medical Licensure Compact, which broadens the pool of available telehealth prescribers.

What the Clinical Evidence Shows for Semaglutide 2.4 mg

Wegovy's FDA approval for chronic weight management rests primarily on the STEP clinical trial program. In STEP-1 (N=1,961), adults with obesity (BMI ≥30) or overweight (BMI ≥27 with at least one comorbidity) who received semaglutide 2.4 mg once weekly achieved a mean body weight loss of 14.9% at 68 weeks, compared to 2.4% with placebo. That 12.5 percentage-point difference was statistically significant (P<0.0001).

Beyond weight loss, the SELECT trial (N=17,604) published in the New England Journal of Medicine in 2023 demonstrated a 20% reduction in major adverse cardiovascular events (MACE) among patients with established cardiovascular disease and overweight or obesity who received semaglutide 2.4 mg versus placebo over a median follow-up of 39.8 months. This cardiovascular benefit led the FDA to expand Wegovy's label in March 2024 to include reduction of cardiovascular risk.

The American Association of Clinical Endocrinology (AACE) 2023 guidelines recommend GLP-1 receptor agonists as first-line pharmacotherapy for patients with obesity and cardiometabolic complications, stating: "Semaglutide 2.4 mg weekly should be considered a preferred agent given its superior efficacy and demonstrated cardiovascular benefit" (AACE consensus statement).

Common adverse effects include nausea (44% vs. 18% placebo in STEP-1), diarrhea (30% vs. 16%), vomiting (24% vs. 6%), and constipation (24% vs. 11%). Most gastrointestinal symptoms occurred during dose escalation and diminished at the maintenance dose. The discontinuation rate due to adverse events was 7.0% with semaglutide versus 3.1% with placebo.

Cheapest Ways to Get Wegovy in Indiana

The most affordable path depends on insurance status. Here is a direct comparison of the main options available to Indiana residents.

Commercially insured with Wegovy coverage: Use the Novo Nordisk savings card to reduce copays, potentially to $0. Annual cost: $0 to $3,000 depending on plan design.

Commercially insured without Wegovy coverage: Appeal the denial. Prescribers can submit a letter of medical necessity citing BMI, comorbidities, and failed lifestyle intervention. If the appeal fails, compounded semaglutide at roughly $199 per month ($2,388 annually) is the next option.

Uninsured: Apply for the Novo Nordisk patient assistance program if household income is below 400% of the federal poverty level ($62,400 for a single individual in 2026). If ineligible for PAP, compounded semaglutide from a licensed 503A pharmacy is the most cost-effective route.

Indiana Medicaid enrollees: No covered pathway exists for weight management. Compounded semaglutide through a telehealth provider is the primary alternative, though this is an out-of-pocket expense.

Discount platforms like GoodRx and RxSaver sometimes show Wegovy coupons for Indiana pharmacies in the $1,200 to $1,300 range, which represents a modest savings of $50 to $150 off the $1,349 list price. These coupons cannot be combined with insurance or the manufacturer savings card.

Patients should also ask their prescriber about the dose-escalation period. During the first 16 weeks, lower doses (0.25 mg through 1.7 mg) are used. Some pharmacies price these lower-dose pens identically to the 2.4 mg maintenance dose, while others charge slightly less.

Indiana-Specific Discount and Assistance Programs

Beyond the Novo Nordisk savings card and PAP, a few Indiana-specific resources may help.

Indiana 211 (dial 2-1-1) connects residents with local prescription assistance programs, community health centers, and sliding-scale clinics. Some federally qualified health centers (FQHCs) in Indiana participate in the 340B Drug Pricing Program, which provides outpatient drugs at significantly reduced costs. If an FQHC prescribes Wegovy and purchases it through 340B channels, the patient may access a lower price, though 340B pricing is not guaranteed to flow through to the patient.

The Indiana Family and Social Services Administration (FSSA) does not operate a standalone prescription drug assistance program for anti-obesity medications. However, patients aged 65 and older or those with disabilities on Medicare Part D may qualify for the Extra Help/Low-Income Subsidy program through the Social Security Administration, which reduces Part D copays. Medicare Part D coverage of Wegovy began in 2026 following the passage of the Treat and Reduce Obesity Act, though formulary placement and prior authorization requirements vary by Part D plan.

Patients should recalculate their options annually. Indiana marketplace plans update formularies each January, and employer-sponsored plans may add GLP-1 coverage at renewal. The trend across the industry is toward broader coverage as cardiovascular outcome data from SELECT strengthens the medical necessity argument.